Currently, the standard treatment of neovascular age-related macular degeneration (AMD) is inhibitors against vascular endothelial growth factor (VEGF), which is a major contributor to the pathogenesis of wet AMD [7]. Here, VEGFA is linked to age-related macular degeneration.